Astrazeneca plc ADR (AZN) concluded trading on Wednesday at a closing price of $66.78, with 5.07 million shares of worth about $338.28 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -16.86% during that period and on December 04, 2024 the price saw a loss of about -1.87%. Currently the company’s common shares owned by public are about 3.10B shares, out of which, 3.10B shares are available for trading.
Stock saw a price change of 0.63% in past 5 days and over the past one month there was a price change of -6.51%. Year-to-date (YTD), AZN shares are showing a performance of -0.85% which increased to 2.71% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $60.47 but also hit the highest price of $87.68 during that period. The average intraday trading volume for Astrazeneca plc ADR shares is 5.45 million. The stock is currently trading 2.24% above its 20-day simple moving average (SMA20), while that difference is down -7.10% for SMA50 and it goes to -10.79% lower than SMA200.
Astrazeneca plc ADR (NASDAQ: AZN) currently have 3.10B outstanding shares and institutions hold larger chunk of about 15.79% of that.
The stock has a current market capitalization of $207.06B and its 3Y-monthly beta is at 0.46. PE ratio of stock for trailing 12 months is 32.09, while it has posted earnings per share of $2.08 in the same period. Its PEG reads 2.67 and has Quick Ratio of 0.71 while making debt-to-equity ratio of 0.78. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AZN, volatility over the week remained 1.00% while standing at 1.60% over the month.
Stock’s fiscal year EPS is expected to rise by 13.39% while it is estimated to increase by 14.08% in next year. EPS is likely to shrink at an annualized rate of 12.00% for next 5-years, compared to annual growth of 17.72% made by the stock over the past 5-years.
On September 13, 2024, Deutsche Bank Downgrade their recommendations, while on May 30, 2024, Goldman Initiated their ratings for the stock with a price target of $97. Stock get a Hold rating from Deutsche Bank on April 16, 2024.
